“Latest Stem Cells News”

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that it has been awarded a $700,000 contract from the U.S. Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center (USAMRMC-TATRC) under U.S. Army Medical Research Acquisition Activity contract number: (W81XWH-10-2-0039).

This contract is for the purpose of evaluating the use of topically applied bone marrow-derived adult mesenchymal stem cells (MSCs) for rapid wound healing. The Company previously announced that this funding was included in the Department of Defense FY09 Appropriations Bill and will begin receiving funds to initiate the program in 2010.

“NeoStem is thrilled to have the United States Government’s support to advance our technology and is honored to become part of TATRC’s regenerative medicine portfolio. It is our goal with this important project to leverage adult stem cell technology to help our soldiers avoid amputations and immobilization from injuries that they may sustain while fighting for our country.

UW-Milwaukee researcher Andrew Cohen has successfully developed a software program that facilitates predicting the evolution of stem cells. The program essentially speeds up what has been a tedious process for researchers in the past.

The program was published last week in the journal Nature Methods. It applies algorithmic information theory to the growth and movement of stem cells tracked over time to show what type of cells (i.e. brain, skin, etc.) they will eventually develop into.

“People look at images and take measurements by hand,” Cohen explained. “It takes a long time, and using computers makes the process a lot less tedious.”

Stem cells all start out the same before they develop into the different cells of our bodies. Scientists do not know what triggers the stem cell’s future growth pattern into a particular type of cell, but researchers like Cohen are figuring out how to predict the cell’s future based on measurements and math.

Two critical programs funded by the California Institute for Regenerative Medicine, the state stem cell agency, got a $11 million increase today when the agency’s 29-member Governing Board voted to approve funding for two additional grants in the Training II program and five additional grants in the Bridges program.

The grants voted in today had been recommended by the Scientific and Medical Research Funding Working Group for funding if funds permit. In January 2009, when the Board considered those applications, they voted to fund only the top tier due to uncertainty in the bond market. With improvements in the state’s bond situation, the Board chose to reconsider the second tier of grants in order to further bolster successful programs training the next generation of stem cell scientists and laboratory staff.

An international team of scientists led by researchers at The Scripps Research Institute has developed a straightforward technique to determine the ethnic origin of stem cells.

The team’s analysis of a variety of human embryonic stem cell lines currently in use in research laboratories around the world found that these cells originated largely from Caucasian and East Asian populations, with little representation from populations originating in Africa. In response to these results, the scientists used skin cells from an individual of West African Yoruba heritage to create a new stem cell line, the first to carry the genetic profile of this ethnic group.

A have-a-go hero who was blinded in one eye in a chemical attack 15 years ago has miraculously got his sight back after undergoing pioneering stem cell treatment.
Russell Turnbull is one of eight patients with impaired vision who have been treated successfully with their own stem cells, in a technique developed by scientists and eye surgeons at the North East England Stem Cell Institute.
Mr Turnbull was hit in his right eye, causing massive damage to the cornea stem cells, leaving him with severely impaired vision, a condition known as Limbal Stem Cell Deficiency (LSCD) (…)

Patents offer the economic guarantees scientists and companies need to develop new treatments, Oliver Bruestle told Deutsche Welle. He’s at the center of a German court battle surrounding embryonic stem cell research

Oliver Bruestle, director of the Institute of Reconstructive Neurobiology at the University of Bonn, is pushing for Germany to recognize the right to patent procedures conducted on embryonic stem cells, saying patents are the right way to ensure that scientists and companies profit from their work.

Greenpeace, however, is opposed to the patents. The organization filed suit against a patent granted to Bruestle in 1999, saying that the patenting of embryonic stem cell research could lead to an “embryo industry.” (…)

There is obviously a lot of hope and hype attached to embryonic stem cell research. Some people imagine a world full of bionic limbs and clones. Is that where the research is headed?

Stem cell research has huge potential for biomedicine mainly because there’s an opportunity to generate essentially every single type of body cell and every single type of tissue artificially in a cell culture lab. This is particularly relevant for organs which have lost their capacity for regeneration. That’s true for the nervous system and the heart as well as for insulin-producing cells. For these tissues, embryonic stem cell lines, which are really the entry point of the patent and procedure, provide a limitless source of cells. We can use these cells to generate insulin-producing cells, heart cells and brain cells in limitless numbers in a cell culture dish (…)

There’s also a lot of fear for people who envision a world full of bionic limbs and organs and clones. Is there potential for this to get out of hand?

There are quite a few misconceptions in the field. For example, we get confronted with accusations that we do research on embryos. This is, in fact, not true. The way the research is done is that there is a possibility to derive what we call embryonic stem cell lines from oocytes, which have been fertilized during artificial insemination or during fertility treatments which are left over and frozen and which are otherwise thrown away in large numbers.

There is an opportunity to use these cells with consent of the parents to derive embryonic stem cell lines and the very special things about these stem cell lines is once they are derived they can be multiplied indefinitely. We can grow them for years, we can freeze them, we can thaw them and they have the remarkable potential that they can be turned into any type of cell in our body.

This field needs a very clear and tight regulation. We certainly have such a situation in Germany. We have one of the toughest embryo protection acts in the world, which essentially prohibits any procedure which is not to the benefit of the embryo. That’s the reason why in Germany we cannot derive embryonic stem cells from fertilized oocytes, which can be done in many other countries (…)

What other possibilities does stem cell research offer that could improve people’s lives?

The prime candidates for stem cell therapies in the nervous system are diseases which lead to a loss of nerve cells or other cells in defined areas. For example, Parkinson’s disease and Huntington’s disease are diseases where we see the loss of very specific types of nerve cells in very specific areas. For replacement therapy, we know where to go and which cell type to put in (…)

from http://www.dw-world.de/dw/article/0,,4898622,00.html